Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

None of these survey matters since the decision

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
yudilks Member Profile
 
Followed By 2
Posts 53
Boards Moderated 0
Alias Born 05/26/20
160x600 placeholder
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/9/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:21:33 PM
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation GlobeNewswire Inc. - 9/3/2020 10:51:52 AM
Traders News Source Issues "Potential Home Run" New Research Report InvestorsHub NewsWire - 9/3/2020 9:00:00 AM
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Ri... GlobeNewswire Inc. - 9/1/2020 4:30:10 PM
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ES... GlobeNewswire Inc. - 8/29/2020 3:13:10 AM
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented... GlobeNewswire Inc. - 8/17/2020 7:00:10 AM
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 8/4/2020 6:00:10 AM
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented ... GlobeNewswire Inc. - 7/27/2020 7:00:10 AM
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire Inc. - 7/21/2020 4:15:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/14/2020 5:20:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Reduction in Coronary Revascularization, Including Coronary Stenting and Cardia... GlobeNewswire Inc. - 5/14/2020 2:50:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 5:19:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/30/2020 6:39:17 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 6:32:26 AM
yudilks   Sunday, 06/21/20 11:46:33 PM
Re: cruyff22 post# 282058
Post # of 301670 
None of these survey matters since the decision won't be based on the result of the survey. Furthermore, most of us here are AMRN investors who would have some degree of bias towards AMRN victory.

If AMRN were really that unlucky, they might get another 2 judges like DUmb Du-Du thus the chance of reversal would be DUmed...

I just hope the reality is otherwise.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences